Epratuzumab Y-90
Alternative Names: 90Y-DOTA-hLL2; 90Y-Epratuzumab; 90Y-hLL2; 90Y-hLL2 IgG; Anti-CD22 monoclonal antibody LL2-Y-90; hCD22-Y-90; IMMU-102; Monoclonal antibody LL2-Y-90; Y-90 epratuzumab tetraxetan; Yttrium-90 epratuzumab tetraxetan; Yttrium-90-labelled epratuzumabLatest Information Update: 24 Oct 2021
At a glance
- Originator Immunomedics
- Developer Immunomedics; Nantes University Hospital; Weill Cornell Medical College
- Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 02 Dec 2020 Immunomedics terminates a phase I/II trial for Non-Hodgkin's lymphoma (Second-line therapy or greater, Combination therapy) in USA as no subjects were enrolled (NCT01101581)
- 02 Dec 2020 Immunomedics terminates a phase I/II trial for Non-Hodgkin's lymphoma (Second-line therapy or greater, Monotherapy) in USA as no subjects were enrolled (NCT01101581)
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences